Bessemer Group’s Terns Pharmaceuticals TERN Stock Holding History

Bessemer Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-541	Closed	-$29K	–	2638
2026 Q1	$29K	Hold	541	–	–	﹤0.01%	1830
2025 Q4	$22K	Buy	+541	New	+$12.5K	﹤0.01%	1860
2024 Q4	–	Sell	-185	Closed	-$2K	–	2686
2024 Q3	$2K	Buy	+185	New	+$1.52K	﹤0.01%	2279

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bessemer Group's TERN Position: Q2 2026 in Review

Bessemer Group sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 541 shares — an estimated $29K sold.

Bessemer Group first reported a position in TERN in Q3 2024 and held it in 3 quarters. The position peaked at $29K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Bessemer Group reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bessemer Group sold 541 Terns Pharmaceuticals shares in Q2 2026, an estimated $29K.
Bessemer Group first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 3 quarters.
Bessemer Group's Terns Pharmaceuticals position peaked at $29K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.